UDK 15 Психология
postmenopausal women have an increased risk of developing osteoporosis. Estrogen deficiency causes an increase in the activity of osteoclastic resorption without a corresponding increase in the activity of osteoblasts, which ultimately leads to a violation of the bone structure. About 200 million women worldwide are affected by osteoporosis; every third woman over 50 suffers an osteoporotic fracture. The risk of developing osteoporosis and fractures varies depending on ethnicity, so black women have a lower risk compared to fair-skinned women, while Spanish and Asian women have a higher risk of osteoporosis, but a similar or lower risk of fractures. Bisphosphonates are one of the most commonly used anti-osteoporosis drugs, acting on osteoclasts, they inhibit bone resorption, thereby minimizing the risk of fractures. This literature review discusses the main methods of treatment of postmenopausal osteoporosis, the most attention is paid to assessing the effectiveness of the use of bisphosphonates.
postmenopausal osteoporosis, bisphosphonates, fracture risk reduction, bone mineral density, SOX9
1. Tella S.H., Gallagher J.C. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014; 142(7):155-170. doi:https://doi.org/10.1016/j.jsbmb.2013.09.008.
2. Komm B.S., Morgenstern D., A Yamamoto L., Jenkins S.N. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Expert Review of Clinical Pharmacology. 2015; 8(6):769-784. doi:https://doi.org/10.1586/17512433.2015.1099432
3. Cosman F. Long-term treatment strategies for postmenopausal osteoporosis. Current Opinion in Rheumatology. 2018; 30(4):420-426. doi:https://doi.org/10.1097/BOR.0000000000000509
4. Baccaro L.F., Conde D.M., Costa-Paiva L., Pinto-Neto A.M. The epidemiology and management of postmenopausal osteoporosis: a viewpoint from Brazil. Clin Interv Aging. 2015; 20(10):583-591. doi:https://doi.org/10.2147/CIA.S54614.
5. Liu H., Zhao H., Lin H., Li Z., Xue H., Zhang Y., Lu J. Relationship of COL9A1 and SOX9 Genes with Genetic Susceptibility of Postmenopausal Osteoporosis. Calcified Tissue International. 2019. doihttps://doi.org/10.1007/s00223-019-00629-7
6. Koevska V., Nikolikj-Dimitrova E., Mitrevska B., Gjeracaroska-Savevska C., Gocevska M., Kalcovska B. Effect of Exercises on Quality of Life in Patients with Postmenopausal Osteoporosis - Randomized Trial. Open access Macedonian journal of medical sciences. 2019; 7(7): 1160-1165. doihttps://doi.org/10.3889/oamjms.2019.271
7. Gambacciani M. The relative contributions of menopause and aging to postmenopausal osteoporosis. Climacteric. 2019; 11(1). doi:https://doi.org/10.1080/13697137.2019.1679114
8. Lv F., Cai X., Yang W., Gao L., Chen L., Wu J., Ji L. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 2019; 130. doi:https://doi.org/10.1016/j.bone.2019.115121.
9. Stepan J.J., Hruskova H., Kverka M. Update on Menopausal Hormone Therapy for Fracture Prevention. Current Osteoporosis Reports. 2019; 11:1-9. doi:https://doi.org/10.1007/s11914-019-00549-3.
10. Hernandez A.V., Pérez-López F.R., Piscoya A., Pasupuleti V., Roman Y.M., Thota P., Herrera A. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Maturitas. 2019; 129:12-22. doihttps://doi.org/10.1016/j.maturitas.2019.08.003
11. Fardellone P., Lello S., Cano A., de Sá Moreira E., Watanabe de Oliveira R., Julian G.S., Tang B. Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review. Clinical Therapeutics. 2019; 41(8):1576-1588. doi: 10.1016 / j. clinthera.2019.05.001.
12. Rouach V., Goldshtein I., Buch A., Catane R., Chodick G., Stern N., Cohen D. The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women. Journal of bone oncology. 2018; 16:100202. doihttps://doi.org/10.1016/j.jbo.2018.10.001
13. Bashir I., Kashif A., Mehreen K., Tayyaba Z., Amna I. Role of Bisphosphonates in Postmenopausal Women with Osteoporosis to Prevent Future Fractures: A Literature Review. Cureus 2019; 11(8): e5328. doihttps://doi.org/10.7759/cureus.5328
14. Pyadushkina E.A., Gerasimova K.V., Goryaynov S.V., Omel'yanovskiy V.V., Avksent'eva M.V., Krysanov I. S. Sravnitel'nyy farmakoekonomicheskiy analiz primeneniya preparata bonviva® (ibandronat) s cel'yu profilaktiki perelomov pri postmenopauzal'nom osteoporoze. Sovremennaya revmatologiya. 2012; 4(12): 89-96.
15. Pineda-Moncusí M., Garcia-Giralt N., Diez-Perez A., Servitja S., Tusquets I., Prieto-Alhambra D., Nogués X. Increased Fracture Risk in Women Treated with Aromatase Inhibitors versus Tamoxifen: Beneficial Effect of Bisphosphonates. Journal of Bone and Mineral Research. 2019. doihttps://doi.org/10.1002/jbmr.3886
16. Morley J., Moayyeri A., Ali L., Taylor A., Feudjo-Tepie M., Hamilton L., Bayly J. Persistence and compliance with osteoporosis therapies among postmenopausal women in the UK Clinical Practice Research Datalink. Osteoporos Int. 2019; 11(22). doi:https://doi.org/10.1007/s00198-019-05228-8
17. Cosman F. Long-term treatment strategies for postmenopausal osteoporosis. Current Opinion in Rheumatology. 2018; 30(4):420-426. doi:https://doi.org/10.1097/BOR.0000000000000509
18. Taylor A.D., Saag K.G. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy. Core Evid. 2019; 14:41-50. doi:https://doi.org/10.2147/CE.S172820
19. Gossiel F., Paggiosi M.A., Naylor K.E., et al. The effect of bisphosphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study. Bone. 2018; 131. doi: 10.1016 / j. bone.2019.115158
20. Schlaff W.D. Introduction: An update on bone metabolism and osteoporosis. Fertil Steril. 2019; 112(5):773-774. doi:https://doi.org/10.1016/j.fertnstert.2019.10.004
21. Marozik P, Alekna V, Rudenko E, Tamulaitiene M, Rudenka A, Mastaviciute A, Samokhovec V, Cernovas A, Kobets K, Mosse I. Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis. PLoS One. 2019; 14(8):e0221511. doi:https://doi.org/10.1371/journal.pone.0221511.
22. Torre C., Guerreiro J., Mendes Z., Miranda A., Bragança F., Cristino J., Canhão H., Branco J.C. Low persistence with oral bisphosphonate treatment in postmenopausal osteoporosis. Acta Reumatol Port. 2019; 44(2):114-125.
